clinical trial · NCT04932291
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
Oryzon Genomics S.A.·phase2·completed·n = 210
Borderline Personality DisordervafidemstatPlacebo
brief summary
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
started
Mar 26, 2021
primary completion
Oct 30, 2023
completion
Nov 13, 2023
last updated
Nov 28, 2023
detailed description
PORTICO is a double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
official title
"A Double-blind, Randomized, Placebo-controlled, Adaptive 14-week Phase IIb Trial to Evaluate the Efficacy and Safety of Vafidemstat in an Adult Borderline Personality Disorder (BPD) Population (PORTICO)"
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol